Cargando…

Prospective, Longitudinal Study on Specific Cellular Immune Responses after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Kidney Transplant Recipients

Solid organ transplant recipients have an up to ninefold higher risk of varicella–zoster virus (VZV) reactivation than the general population. Due to lifelong immunosuppressive therapy, vaccination against VZV may be less effective in kidney transplant (KTX) recipients. In the current study, twelve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lindemann, Monika, Baumann, Charleen, Wilde, Benjamin, Gäckler, Anja, Meller, Lara, Horn, Peter A., Krawczyk, Adalbert, Witzke, Oliver
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9227383/ https://www.ncbi.nlm.nih.gov/pubmed/35746452 http://dx.doi.org/10.3390/vaccines10060844

Ejemplares similares

Cellular Immune Response after Vaccination with an Adjuvanted, Recombinant Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Koldehoff, Michael, et al.
Publicado: (2022)

Establishment of an ELISpot Assay to Detect Cellular Immunity against S. pneumoniae in Vaccinated Kidney Transplant Recipients
por: Gäckler, Anja, et al.
Publicado: (2021)

Correlation of Fc Receptor Polymorphisms with Pneumococcal Antibodies in Vaccinated Kidney Transplant Recipients
por: Arnold, Marie-Luise, et al.
Publicado: (2022)

Cellular and Humoral Immunity against Different SARS-CoV-2 Variants Is Detectable but Reduced in Vaccinated Kidney Transplant Patients
por: Thümmler, Laura, et al.
Publicado: (2022)

Antibody responses after sequential vaccination with PCV13 and PPSV23 in kidney transplant recipients
por: Mülling, Nils, et al.
Publicado: (2023)

Cellular and Humoral Immunity after the Third Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplant Recipients
por: Thümmler, Laura, et al.
Publicado: (2022)

Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients
por: Thümmler, Laura, et al.
Publicado: (2022)

Comparison of Humoral and Cellular CMV Immunity in Patients Awaiting Kidney Transplantation
por: Lindemann, Monika, et al.
Publicado: (2021)

Sex-Specific Differences in HLA Antibodies after Pneumococcal Vaccination in Kidney Transplant Recipients
por: Lindemann, Monika, et al.
Publicado: (2019)

Long-term cellular immune response in immunocompromised unvaccinated COVID-19 patients undergoing monoclonal antibody treatment
por: Thümmler, Laura, et al.
Publicado: (2022)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

4. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine
por: Dagnew, Alemnew F, et al.
Publicado: (2020)

Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age
por: Konik, Margarethe, et al.
Publicado: (2021)

Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
por: Tavares-Da-Silva, Fernanda, et al.
Publicado: (2020)

Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live
por: Curran, Desmond, et al.
Publicado: (2019)

Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice
por: Stadtmauer, Edward A., et al.
Publicado: (2021)

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

An update on national recommendations for the use of the adjuvanted recombinant zoster vaccine: Romy Weller
por: Parikh, R, et al.
Publicado: (2022)

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
por: Korth, Johannes, et al.
Publicado: (2021)

Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine
por: Ilyas, Sahrish, et al.
Publicado: (2020)

Low efficacy of vaccination against serogroup B meningococci in patients with atypical hemolytic uremic syndrome
por: Mülling, Nils, et al.
Publicado: (2020)

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
por: Dagnew, Alemnew F., et al.
Publicado: (2021)

Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials
por: López-Fauqued, Marta, et al.
Publicado: (2021)

Cost-Effectiveness Analysis Update of the Adjuvanted Recombinant Zoster Vaccine in Japanese Older Adults
por: Teng, Lida, et al.
Publicado: (2022)

BTK inhibitors impair humoral and cellular responses to recombinant zoster vaccine in CLL
por: Pleyer, Christopher, et al.
Publicado: (2022)

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
por: Curran, Desmond, et al.
Publicado: (2019)

Cost-Effectiveness of the Adjuvant Recombinant Zoster Vaccine in Japanese Adults Aged 65 Years and Older
por: Shiragami, Makoto, et al.
Publicado: (2019)

Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines
por: Pleyer, Christopher, et al.
Publicado: (2021)

An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine
por: Pirrotta, Paola, et al.
Publicado: (2021)

Boosting Immunity in Recipients of Live-Attenuated Zoster Vaccine
por: Schmid, D. Scott
Publicado: (2016)

Uveitis reactivation following recombinant zoster vaccination
por: Richards, Paige J., et al.
Publicado: (2021)

Thrombotische Mikroangiopathie: Diagnose und Therapie
por: Gäckler, Anja, et al.
Publicado: (2021)

The Cytomegalovirus-Specific IL-21 ELISpot Correlates with Allograft Function of Kidney Transplant Recipients
por: Lindemann, Monika, et al.
Publicado: (2018)

An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21
por: Nam, Hyo Jung, et al.
Publicado: (2022)

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
por: Strezova, Ana, et al.
Publicado: (2022)

Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme
por: van Oorschot, Desirée A M, et al.
Publicado: (2019)

Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial
por: Vink, Peter, et al.
Publicado: (2019)

Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination
por: Hastie, Andrew, et al.
Publicado: (2020)

Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults
por: McGirr, Ashleigh, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_92oqtom5nvpf02lcgu53scnjqe